H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc.

H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc., a Tampa, Florida–based nonprofit hospital and National Cancer Institute–designated comprehensive cancer center, receives federal research grants and contracts as a prime recipient for cancer research, clinical trials, and biomedical investigation performed primarily at its Tampa facility and subordinate locations, with no set-aside designations.

Moffitt operates almost entirely in the research and development space. The center's concrete capability profile centers on cancer biology research, translational oncology, clinical trial design and execution, immunotherapy development, biomarker discovery, and precision medicine across solid and hematologic malignancies. Recent representative work includes a $2.99 million National Cancer Institute grant (CFDA 93.393) awarded September 2025 to characterize lung cancer screening trends among people with HIV using electronic health record linkage across Florida; an $18.7 million Defense Health Agency Cooperative Agreement (CFDA 12.420) awarded September 2025 to develop and evaluate dendritic cell therapies for breast cancer leptomeningeal disease; a $2.44 million National Institute of Standards and Technology grant (CFDA 11.617) awarded September 2024 to acquire high-precision microscopy systems for imaging tumor models; and a $589,581 National Cancer Institute grant (CFDA 93.395) awarded September 2026 to optimize gamma/delta CAR-T-cell therapy for bone metastatic castration-resistant prostate cancer. The center also conducts investigator-initiated research in melanoma biology, metabolic adaptation in cancer, epigenetic regulation, immune checkpoint biology, and cancer survivorship outcomes.

Federal funding is heavily concentrated in the National Institutes of Health ecosystem. The National Cancer Institute dominates by award count (326 awards, $22.8 million combined potential value), followed distantly by the Defense Health Agency (74 awards) and the National Heart, Lung, and Blood Institute (22 awards, $80.2 million combined potential value). Across the top five customer agencies, Moffitt serves 37 distinct federal agencies in total. The center operates as a prime recipient on the vast majority of awards (79% of 769 total awards), with 21% as a subrecipient on larger consortium efforts. Recent subrecipient work includes participation in consortium studies led by Mayo Clinic, University of Florida, MD Anderson Cancer Center, and Fred Hutchinson Cancer Center.

SCI-reportable service contract activity (which captures federal contracts above the $150,000 threshold and excludes grants, goods, and non-federal revenue) shows $24.6 million in invoiced revenue across FY2022–FY2025, with the largest year in FY2024 at $11.7 million. Government-paid hourly rates on SCI contracts show wide variance—median around $700/hr with 10th percentile at $182/hr and 90th percentile reaching six figures—reflecting a mix of senior researcher effort, core facility services, and specialized scientific labor. Across SCI-reportable prime contracts, the center reports zero average sub-hours share, indicating delivery built largely on in-house capacity rather than subcontracted labor.

Moffitt's corporate structure includes a named subsidiary, H. Lee Moffitt Cancer Center And Research Institute Lifetime Cancer Screening Center, Inc., a nonprofit DBE-certified entity focused on cancer prevention and screening.

The center faces a modest recompete cliff: 64 awards with ultimate completion in the next twenty-four months carry only $148 thousand in combined potential value, signaling limited near-term revenue exposure from expiring grants. Activity has remained robust, with 50–94 awards per year over the past five years and a long tail of active grants and cooperative agreements extending through 2031. The award footprint is characteristic of an academic comprehensive cancer center: heavy concentration in basic and applied cancer research via NIH project grants, relatively light contract-service activity, and positioning as a prime recipient in consortium research networks anchored by larger health systems and research universities.